Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Thomas Müller. (2023) The role of istradefylline in the Parkinson’s disease armamentarium. Expert Opinion on Pharmacotherapy 24:7, pages 863-871.
Read now
Read now
Thomas Müller. (2021) Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence. Journal of Experimental Pharmacology 13, pages 397-408.
Read now
Read now
Thomas Müller. (2021) View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track?. Biologics: Targets and Therapy 15, pages 307-316.
Read now
Read now
Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Read now
Thomas Müller & Jan-Dominique Möhr. (2019) Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. Expert Opinion on Drug Metabolism & Toxicology 15:5, pages 429-435.
Read now
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Long-term management of Parkinson’s disease using levodopa combinations. Expert Opinion on Pharmacotherapy 19:9, pages 1003-1011.
Read now
Read now
Marina Svetel, Aleksandra Tomić, Nikola Kresojević & Vladimir Kostić. (2018) Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 14:3, pages 353-360.
Read now
Read now
Thomas Müller. (2018) ABCB1: is there a role in the drug treatment of Parkinson’s disease?. Expert Opinion on Drug Metabolism & Toxicology 14:2, pages 127-129.
Read now
Read now
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
Siegfried Muhlack, Manuel Kinkel, Lennard Herrman & Thomas Müller. (2017) Levodopa, placebo and rotigotine change biomarker levels for oxidative stress. Neurological Research 39:5, pages 381-386.
Read now
Read now
Peter Riederer & Thomas Müller. (2017) Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 233-240.
Read now
Read now
Thomas Müller & Paul Foley. (2016) Clinical drug research in chronic central neurodegenerative disorders. Expert Review of Neurotherapeutics 16:5, pages 497-504.
Read now
Read now
Thomas Müller. (2015) The safety of istradefylline for the treatment of Parkinson’s disease. Expert Opinion on Drug Safety 14:5, pages 769-775.
Read now
Read now
Thomas Müller. (2014) Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 10:10, pages 1423-1432.
Read now
Read now
Articles from other publishers (21)
Xingwei Li, Caixia Yin, Le Zhang & Fangjun Huo. (2023) Research progress of small molecule fluorescent probes for liver cancer related enzymes. Dyes and Pigments 219, pages 111631.
Crossref
Crossref
Xiao-Zhong Jing, Xiang-Zhen Yuan, Xingguang Luo, Shu-Yun Zhang & Xiao-Ping Wang. (2023) An Update on Nondopaminergic Treatments for Motor and Non-motor
Symptoms of Parkinson’s Disease. Current Neuropharmacology 21:8, pages 1806-1826.
Crossref
Crossref
Adriana Trapani, Stefano Castellani, Lorenzo Guerra, Elvira De Giglio, Giuseppe Fracchiolla, Filomena Corbo, Nicola Cioffi, Giuseppe Passantino, Maria Luana Poeta, Pasqualina Montemurro, Rosanna Mallamaci, Rosa Angela Cardone & Massimo Conese. (2023) Combined Dopamine and Grape Seed Extract-Loaded Solid Lipid Nanoparticles: Nasal Mucosa Permeation, and Uptake by Olfactory Ensheathing Cells and Neuronal SH-SY5Y Cells. Pharmaceutics 15:3, pages 881.
Crossref
Crossref
Thomas Müller. (2022) Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson’s Disease, Necessary Again?. Cells 12:1, pages 157.
Crossref
Crossref
Thomas Müller. (2022)
GOCOVRI
®
(amantadine) extended-release capsules in Parkinson's disease
. Neurodegenerative Disease Management 12:1, pages 15-28.
Crossref
Crossref
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2853
2870
.
Weibo Xu, Jian Wang, Chenyang Xu, Jianli Hua & Yu Wang. (2021) A diketopyrrolopyrrole-based ratiometric fluorescent probe for endogenous leucine aminopeptidase detecting and imaging with specific phototoxicity in tumor cells. Journal of Materials Chemistry B 9:42, pages 8842-8850.
Crossref
Crossref
Thomas Müller, Bernhard Klaus Mueller & Peter Riederer. (2021) Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. Cells 10:4, pages 873.
Crossref
Crossref
Tracy Lister. (2020) Nutrition and Lifestyle Interventions for Managing Parkinson’s Disease: A Narrative Review. Journal of Movement Disorders 13:2, pages 97-104.
Crossref
Crossref
Thomas Müller. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
18
.
Shuailing Huang, Yinglong Wu, Fang Zeng, Junjie Chen & Shuizhu Wu. (2018) A turn-on fluorescence probe based on aggregation-induced emission for leucine aminopeptidase in living cells and tumor tissue. Analytica Chimica Acta 1031, pages 169-177.
Crossref
Crossref
Thomas Müller & Willi Kohlhepp. (2018) Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson’s disease. Medical Hypotheses 110, pages 46-49.
Crossref
Crossref
Carsten Buhmann, R. Hilker, P. Lingor, C. Schrader, J. Schwarz, M. Wolz & H. Reichmann. (2017) Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. Journal of Neural Transmission 124:8, pages 1005-1013.
Crossref
Crossref
Gonul Vural, Sadiye Gumusyayla, Hesna Bektas, Orhan Deniz, Murat Alisik & Ozcan Erel. (2017) Impairment of dynamic thiol–disulphide homeostasis in patients with idiopathic Parkinson’s disease and its relationship with clinical stage of disease. Clinical Neurology and Neurosurgery 153, pages 50-55.
Crossref
Crossref
Xinyuan He, Lihong Li, Yu Fang, Wen Shi, Xiaohua Li & Huimin Ma. (2017) In vivo imaging of leucine aminopeptidase activity in drug-induced liver injury and liver cancer via a near-infrared fluorescent probe. Chemical Science 8:5, pages 3479-3483.
Crossref
Crossref
Thomas Müller. (2016) Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management 6:5, pages 385-398.
Crossref
Crossref
Thomas Müller, Isabel Trommer, Siegfried Muhlack & Bernhard K. Mueller. (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. Journal of Neural Transmission 123:4, pages 401-406.
Crossref
Crossref
Thomas Müller. (2016) Do we need a new levodopa?. Neural Regeneration Research 11:5, pages 731.
Crossref
Crossref
Thomas Müller. (2015) Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease. Drugs 75:2, pages 157-174.
Crossref
Crossref
Jin Yong Hong, Hyuk Jin Yun, Mun Kyung Sunwoo, Jee Hyun Ham, Jong-Min Lee, Young H. Sohn & Phil Hyu Lee. (2014) Cognitive and cortical thinning patterns of subjective cognitive decline in patients with and without Parkinson's disease. Parkinsonism & Related Disorders 20:9, pages 999-1003.
Crossref
Crossref
Thomas Müller & Siegfried Muhlack. (2014) Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients. Journal of Neural Transmission 121:6, pages 643-648.
Crossref
Crossref